Abstract
Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 580-585 |
| Number of pages | 6 |
| Journal | Journal of Cardiovascular Pharmacology |
| Volume | 13 |
| Issue number | 4 |
| State | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology
Cite this
Efficacy and safety of isradipine in hypertension. / Shepherd, Alexander M; Carr, A. A.; Davidov, M.; Hamilton, J.; Schnaper, H.; Velasquez, M.; Brockway, B.; Prisant, L. M.; Hamilton, B.; Gonasun, L.
In: Journal of Cardiovascular Pharmacology, Vol. 13, No. 4, 1989, p. 580-585.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of isradipine in hypertension
AU - Shepherd, Alexander M
AU - Carr, A. A.
AU - Davidov, M.
AU - Hamilton, J.
AU - Schnaper, H.
AU - Velasquez, M.
AU - Brockway, B.
AU - Prisant, L. M.
AU - Hamilton, B.
AU - Gonasun, L.
PY - 1989
Y1 - 1989
N2 - Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.
AB - Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.
UR - http://www.scopus.com/inward/record.url?scp=0024564926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024564926&partnerID=8YFLogxK
M3 - Article
C2 - 2470995
AN - SCOPUS:0024564926
VL - 13
SP - 580
EP - 585
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
SN - 0160-2446
IS - 4
ER -